Multiple legal actions tied to alleged safety and disclosure issues around Insulet (PODD) and its Omnipod insulin delivery products have put the stock under closer scrutiny for many investors.

Against this backdrop of product safety concerns and fresh lawsuits, Insulet’s share price has had mixed momentum, with a 90 day share price return of 10.27% but a year to date share price decline of 41.04% and a 1 year total shareholder return decline of 40.63%.

If you want to look beyond Insulet and see what else is moving in the sector, this is a good moment to scan for other healthcare related opportunities through our 41 healthcare AI stocks.

Recent gains for Insulet sit against steep longer term share price declines, which raises a simple question: Are investors reassessing the strength of the underlying Omnipod business, or just swinging back on sentiment after the legal shocks?

Most Popular Narrative: 29.2% Undervalued

Insulet’s most followed narrative points to a fair value of $235.54 against the last close at $166.82. This frames the current legal headlines against a much higher long term valuation anchor.

Rapidly rising adoption of Omnipod 5 in both the U.S. and international markets, driven by strong clinical evidence, ease of use, and superior integration with the latest glucose sensors, is positioning Insulet to capture a disproportionately large share of the expanding global diabetes device market, supporting outsized top-line revenue growth for several years.

Curious what sits behind that confidence in Insulet? The narrative leans on stepped up revenue expectations, rising profitability and a lower future earnings multiple to justify that higher fair value.

Result: Fair Value of $235.54 (UNDERVALUED)

However, Insulet’s heavy dependence on the Omnipod platform, along with ongoing product recalls and class action lawsuits, could unsettle demand expectations and challenge that upbeat narrative.

Another View on Insulet’s Valuation

The analyst narrative classifies Insulet as undervalued relative to a fair value of $235.54, yet the market is currently paying a P/E of 38.2x. That is slightly above both peer companies at 37.9x and the US Medical Equipment industry at 31.9x, and also above a fair ratio of 32.9x. For investors, that gap can mean paying up today for expectations that may already be priced in.

It raises a simple question for anyone looking at Insulet now: Is the current price more in line with a richer growth story, or will the market eventually move closer to that lower fair ratio and compress the P/E?

Next Steps

With mixed signals around Insulet’s valuation and legal risks, it makes sense to check the underlying data yourself and move quickly while sentiment is still split. To weigh up both the potential rewards and the issues investors are worried about, take a closer look at the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Insulet?

If you are serious about improving your process, do not stop with Insulet. Fresh ideas from different corners of the market can sharpen your next move.

• Spot potential value opportunities early by checking out companies flagged in our 52 high quality undervalued stocks.
• Strengthen the defensive side of your portfolio by reviewing stocks in the 82 resilient stocks with low risk scores.
• Hunt for less crowded opportunities by scanning the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.